Lupin gets USFDA nod for amifampridine tablets, eligible for 180-day generic exclusivity

Lupin has received USFDA approval for its Amifampridine Tablets, 10 mg, and is eligible for 180 days of shared generic exclusivity as one of the first applicants to file. The drug is bioequivalent to Catalyst Pharmaceuticals' Firdapse Tablets, 10 mg.